Timothy Clay

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.

Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Daphne Day, Andrew G Hill, Steven J O'Day, Timothy D Clay, Gavin M Wright, Ross R Jennens, David E Gerber, Jonathan E Rosenberg, Christy Ralph, David C Campbell, Brendan D Curti, Jaime R Merchan, Yixin Ren, Emmett V Schmidt, Lisa Guttman, et al.

Journal article  |  2023  |  J Immunother Cancer

BACKGROUND: Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intrave..

The impact of the 2022 Ukraine/Russian conflict on cancer clinical trials.

Alice Talbot, Sophia G Connor, Kate Austin, Tara Hannon, Eli Gabbay, Timothy D Clay

Journal article  |  2022  |  J Int Med Res

Since the invasion of Ukraine in February 2022, clinical trial conduct has become extremely challenging due to damage to the healt..

Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer.

Jin-Soo Kim, Dennis R Taaffe, Daniel A Galvão, Timothy D Clay, Andrew D Redfern, Nicolas H Hart, Elin S Gray, Charles J Ryan, Stacey A Kenfield, Fred Saad, Robert U Newton

Journal article  |  2022  |  Prostate Cancer Prostatic Dis

PURPOSE: Although skeletal muscle releases cytokines called myokines during exercise, the kinetics of the acute myokine response t..

Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series.

Sarah Picard, Desiree Goh, Ashley Tan, Nisha Sikotra, Eli Gabbay, Tim Clay

Journal article  |  2021  |  J Med Case Rep

BACKGROUND: Immunotherapy has become an efficacious option in the management of solid organ malignancies. Immune-related adverse e..

Doctors' understanding of consent law

Rohen Skiba, Nisha Sikotra, Alexandra Wilson, Timothy D Clay, Eli Gabbay

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

BACKGROUND: Obtaining informed consent is an important responsibility of all doctors and is a major component of their day-to-day ..

Dilemmas in anticoagulation and use of inferior vena cava filters in venous thromboembolism; a survey of Respiratory Physicians, Haematologists and Medical Oncologists and a review of the literature.

Philip Craven, Ciara Daly, Nisha Sikotra, Tim Clay, Eli Gabbay

Journal article  |  2021  |  Pulm Circ

Twenty percent of patients with Cancer Associated Thrombosis receive an inferior vena cava filter annually. Insertion is guided by..

Metastatic seminoma in a 77-year-old man with a regressed primary tumour and concurrent high-grade superficial bladder cancer

T England, M England, T Clay, P England

Journal article  |  2021  |  Journal of Clinical Urology

Management of neutropenic fever in a private hospital oncology unit

Rohen Skiba, Nisha Sikotra, Timothy Ball, Astrid Arellano, Eli Gabbay, Timothy D Clay

Journal article  |  2020  |  INTERNAL MEDICINE JOURNAL

BACKGROUND: Neutropenic fever is a medical emergency, which poses a significant morbidity and mortality risk to cancer patients re..

Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic

Eva Segelov, Craig Underhill, Hans Prenen, Christos Karapetis, Christopher Jackson, Louise Nott, Tim Clay, Nick Pavlakis, Sabe Sabesan, Ellen Heywood, Christopher Steer, Carrie Lethborg, Hui K Gan, Desmond Yip, Narayan Karanth, Deme Karikios, C Raina MacIntyre

Journal article  |  2020  |  JCO ONCOLOGY PRACTICE

Cancer has become a prevalent disease, affecting millions of new patients globally each year. The COVID-19 pandemic is having far-..

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Daniel P Petrylak, Ronald de Wit, Kim N Chi, Alexandra Drakaki, Cora N Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed A Hussain, Aude Fléchon, Aristotelis Bamias, Evan Y Yu, Michiel S van der Heijden, Nobuaki Matsubara, Boris Alekseev, Andrea Necchi, Lajos Géczi, Yen-Chuan Ou, Hasan Senol Coskun, Wen-Pin Su, Jens Bedke, et al.

Journal article  |  2020  |  Lancet Oncol

BACKGROUND: Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonist-plus docetaxel was previously reported to..